Burke Michael, Rashdan Sawsan
Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Front Oncol. 2021 Sep 30;11:720759. doi: 10.3389/fonc.2021.720759. eCollection 2021.
With proven efficacy of the use of immunotherapy in almost all stages of NSCLC, immunotherapy toxicity has become a very important topic that requires immediate recognition and management. The diagnosis of toxicities associated with immunotherapy in lung cancer can be very challenging and often requires multidisciplinary effort. This mini review gives an overview of the diagnosis and management of immune-related adverse events that arise from using immunotherapy in NSCLC, as well as the potential biomarkers for its early identification and future directions.
鉴于免疫疗法在非小细胞肺癌（NSCLC）几乎所有阶段都已证实具有疗效，免疫疗法的毒性已成为一个非常重要的话题，需要立即识别和处理。肺癌中与免疫疗法相关的毒性诊断可能极具挑战性，通常需要多学科协作。本综述概述了在NSCLC中使用免疫疗法引发的免疫相关不良事件的诊断和管理，以及其早期识别的潜在生物标志物和未来方向。
